QCM Cayman’s Jazz Pharmaceuticals JAZZ Stock Holding History

QCM Cayman’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,533	Closed	-$238K	–	194
2017 Q2	$238K	Buy	+1,533	New	+$234K	0.54%	92
2015 Q4	–	Sell	-5,038	Closed	-$669K	–	216
2015 Q3	$669K	Buy	+5,038	New	+$867K	0.22%	45
2014 Q4	–	Sell	-1,470	Closed	-$236K	–	275
2014 Q3	$236K	Buy	+1,470	New	+$226K	0.05%	150
2014 Q2	–	Sell	-3,358	Closed	-$466K	–	294
2014 Q1	$466K	Buy	+3,358	New	+$505K	0.1%	124

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QCM Cayman's JAZZ Position: Q3 2017 in Review

QCM Cayman sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 1,533 shares — an estimated $238K sold.

QCM Cayman first reported a position in JAZZ in Q1 2014 and held it in 4 quarters. The position peaked at $669K in Q3 2015. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

QCM Cayman reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
QCM Cayman sold 1,533 Jazz Pharmaceuticals shares in Q3 2017, an estimated $238K.
QCM Cayman first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 4 quarters.
QCM Cayman's Jazz Pharmaceuticals position peaked at $669K in Q3 2015.
303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on QCM Cayman's 13F filing for Q3 2017, filed 14 Nov 2017.